Table 3.
Distribution and median survival of patients with hepatocellular carcinoma according to the studied staging systems
| Staging/grading system | Stage/grade | Percentage of patients | Median survival (mo) | P-value |
| CTP | A | 50.6 | 19 | < 0.001 |
| B | 36.1 | 11 | ||
| C | 13.4 | 3.8 | ||
| BCLC | 0 | 3.6 | 25.4 | < 0.001 |
| A | 27.5 | 19.8 | ||
| B | 26.6 | 16 | ||
| C | 28.9 | 8 | ||
| D | 13.4 | 4 | ||
| TNM | I | 19.5 | 23 | < 0.001 |
| II | 36.6 | 18 | ||
| III | 35.4 | 8 | ||
| IV | 8.5 | 6 | ||
| ALBI | 1 | 12 | 28.6 | < 0.001 |
| 2 | 63.2 | 14 | ||
| 3 | 24.7 | 5.8 | ||
| PALBI | 1 | 10.1 | 34.6 | < 0.001 |
| 2 | 29 | 27.5 | ||
| 3 | 33.9 | 23.9 | ||
| 4 | 27 | 7.5 | ||
| ALBI-based BCLC | 0 | 1.5 | Undefined | < 0.001 |
| A | 5.9 | 30.8 | ||
| B | 67.2 | 14.2 | ||
| C | 2.2 | 11 | ||
| D | 23.2 | 5 | ||
| ALBI-T | 0 | 2.6 | 42 | < 0.001 |
| 1 | 18.1 | 28.9 | ||
| 2 | 30.4 | 17 | ||
| 3 | 31.1 | 8 | ||
| 4 | 16 | 5 | ||
| 5 | 1.8 | 3 | ||
| Modified ALBI-T | 0 | 2.6 | 42 | < 0.001 |
| 1 | 9.1 | 28.9 | ||
| 2 | 18.5 | 20 | ||
| 3 | 27.9 | 14 | ||
| 4 | 25.5 | 8 | ||
| 5 | 14.6 | 5 | ||
| 6 | 1.8 | 3 |
CTP: Child-Turcotte-Pugh score; ALBI: Albumin-bilirubin score; TNM: Tumor-node-metastasis staging system; BCLC: Barcelona Clinic Liver Cancer staging system.